摘要
目的探讨肝动脉插管化疗栓塞术(transcatheter arterial chemoembolization,TACE)联合仑伐替尼治疗中晚期肝癌的临床疗效。方法选取2018年8月—2021年3月于广州市第十二人民医院住院的中晚期肝癌患者58例为研究对象,随机分为对照组和研究组,各29例。对照组应用TACE治疗,研究组应用仑伐替尼联合TACE治疗。比较两组治疗前后的肝功能[血清胆红素(TBIL)、甲胎蛋白(AFP)、丙谷转氨酶(ALT)、谷草转氨酶(AST)]变化情况、癌症治疗功能总体评价量表(FACT-G)评分情况以及治疗效果。结果研究组治疗后TBIL、AFP、ALT、AST水平均比对照组低,差异有统计学意义(t=6.153、7.349、6.456、24.307,P<0.001);研究组总有效率(96.55%)比对照组(72.41%)高,差异有统计学意义(χ^(2)=4.735,P=0.030);研究组治疗后情感状况、生理状况、功能状况、家庭和社会状况评分均比对照组高,差异有统计学意义(t=10.801、9.749、14.928、13.987,P<0.001)。结论中晚期肝癌患者应用TACE介入治疗联合仑伐替尼治疗效果更佳,有利于患者肝肾功能、治疗效果以及总体功能的提高。
Objective To explore the clinical efficacy of hepatic transcatheter arterial chemoembolization(TACE)therapy combined with lenvatinib in the treatment of intermediate to advanced hepatocellular carcinoma.Methods 58 patients with advanced liver cancer who were hospitalized in the Guangzhou Twelfth People's Hospital from August 2018 to March 2021 were selected as the study subjects.They were randomly divided into control group and study group,with 29 cases each.The control group applied TACE treatment,and the study group applied lenvatinib combined with TACE treatment.The liver function[total bilirubin(TBIL),alpha-fetoprotein(AFP),alanine aminotransferase(ALT),aspartate transaminase(AST)],Functional Assessment of Cancer Therapy Scale(FACT-G)scores,and treatment effects before and after treatment were compared in two groups.Results The levels of TBIL,AFP,ALT and AST in the study group were lower than those in the control group after treatment,and the difference was statistically significant(t=6.153,7.349,6.456,24.307,P<0.001);the total effective rate was higher in the study group(96.55%)than in the control group(72.41%),and the difference was statistically significant(χ^(2)=4.735,P=0.030);the emotional status,physical status,functional status,family and social status scores were higher in the study group than in the control group after treatment,and the difference was statistically significant(t=10.801,9.749,14.928,13.987,P<0.001).Conclusion TACE intervention combined with lenvatinib is more effective in patients with intermediate to advanced hepatocellular carcinoma,which is beneficial to the improvement of liver and kidney function,therapeutic effect and overall function.
作者
马萍
周元敏
盖云竹
叶更新
MA Ping;ZHOU Yuanmin;GAI Yunzhu;YE Gengxin(Department of Oncology,Guangzhou Twelfth People's Hospital,Guangzhou,Guangdong Province,510620 China)
出处
《系统医学》
2022年第24期173-177,共5页
Systems Medicine
基金
广州市医药卫生科技项目(20161A011044)。
关键词
TACE介入治疗
仑伐替尼
中晚期肝癌
治疗效果
TACE intervention
Lenvatinib
Intermediate and advanced hepatocellular carcinoma
Therapeutic effect
作者简介
马萍(1973-),女,本科,主治医师,研究方向为肿瘤内科;通信作者:叶更新(1965-),男,本科,副主任医师,研究方向为放射介入学,E-mail:maping00210@126.com。
